Lab study tests Iron-Binding drug on Parkinson's and ALS cells
NCT ID NCT02880033
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how the drug deferiprone affects blood cells from 90 people with Parkinson's disease, ALS, or healthy volunteers. Researchers measured markers of oxidative stress and iron levels in the lab. The goal was to better understand these diseases, not to treat patients directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- deferiprone
- What this could lead to
- If successful, this could help researchers understand how iron and oxidative stress contribute to Parkinson's and ALS, potentially guiding future treatments.
- What could go wrong
- This is a very early, lab-based study using cells from patients, not a treatment trial. Results may not translate to real-world benefits for patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Roger Salengro, CHRU de Lille
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Could a brain disease change behavior years before diagnosis?
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's
- Can a cancer drug slow ALS? a trial aims to find out
- Can conversation unlock clues to ALS speech decline?
- Could a mushroom compound turn back the clock on aging?